Document:

<PAGE>

                                                                    Exhibit 4.33

(PROTHERICS LOGO)

21 July 2005

Mr Bryan Morton
Zeneus Pharma Ltd
Magdalen Centre
Oxford Science Park
Oxford
OX4 4GA

Dear Bryan

               PROTHERICS PLC (THE "COMPANY") AND YOUR APPOINTMENT
                    TO THE BOARD AS A NON-EXECUTIVE DIRECTOR

Following the recommendation of the nomination committee, the board of the
Company (the "Board") is pleased to hear that you have accepted our offer to
join on the Board as a non-executive director with effect from 1 August 2005.
This letter confirms the main terms of your appointment to this office. You
should be aware that your appointment will have to be ratified by the Company's
shareholders at the annual general meeting following your appointment, and is
subject to the Company's articles of association as amended from time to time.
If there is a conflict between the terms of this letter and the articles of
association then the articles shall prevail.

DUTIES

1.   You will be informed how the Board is structured and what authorities are
     delegated to the Chief Executive and his colleagues.

2.   The Board as a whole is collectively responsible for promoting the success
     of the Company by directing and supervising the Company's affairs. The
     Board's role is to:

     (a)  provide entrepreneurial leadership to the Company within a framework
          of prudent and effective controls which enable risk to be assessed and
          managed;

                                                    Protherics PLC
                                                    Fourth Floor
                                                    3 Creed Court
                                                    5 Ludgate Hill
Registered Office                                   London EC4M 7AA
Registered in England No. 2459087                   Tel: 0207 246 9950
Protherics PLC, The Heath Business and              Fax: 0207 329 5924
Technical Park,                                     Web Site: www.protherics.com
Runcorn, Cheshire WA74QF

<PAGE>

                                        2

     (b)  set the Company's strategic aims, ensure that the necessary financial
          and human resources are in place for the Company to meet its
          objectives, and review management performance; and

     (c)  set the Company's values and standards and ensure that its obligations
          to its shareholders and others are understood and met.

3.   In your role as a non-executive director you are required (with the other
     non-executives) to:

     (a)  constructively challenge and contribute to the development of
          strategy;

     (b)  scrutinise the performance of management in meeting agreed goals and
          objectives and monitor the reporting of performance;

     (c)  satisfy yourself that financial information is accurate and that
          financial controls and systems of risk management are robust and
          defensible;

     (d)  be responsible for determining appropriate levels of remuneration of
          executive directors and have a prime role in appointing, and where
          necessary removing, senior management and in succession planning.

4.   You will be required to:

     (a)  exercise relevant powers under the Company's memorandum and articles
          of association;

     (b)  perform your duties faithfully, efficiently and diligently and use all
          reasonable endeavours to promote the interests and reputation of the
          Company;

     (c)  comply with your fiduciary duties;

     (d)  report the wrongdoing (including acts of misconduct, dishonesty,
          breaches of contract, fiduciary duty, company rules or the rules of
          the relevant regulatory bodies) whether committed, contemplated or
          discussed by any other director or member of staff of the Company and
          any group company of which you were aware to the Board immediately,
          irrespective of whether this may involve some degree of self
          incrimination;

     (e)  serve on the nomination, audit and remuneration committees of the
          Board and attend, wherever possible, all meetings of the committees
          (committee meetings may occasionally be scheduled separately from
          Board meetings);

<PAGE>

                                       3

     (f)  attend all general meetings of the Company;

     (g)  attend, wherever possible, all meetings of the Board, which meets on
          an agreed schedule (in 2005, 9 meetings are scheduled). These are
          mostly at the Company's offices at Ludgate Hill, London, with
          occasional meetings at other Company locations;

     (h)  consider all relevant papers in advance of each meeting in order to
          ensure that you can play a full part in the work of the Board and its
          committees;

     (i)  bring independent judgement to bear on issues of strategy, policy,
          resources, performance and standards of conduct;

     (j)  make yourself available (on reasonable notice) to provide ad hoc
          advice to individual directors of the Company;

     (k)  provide guidance and direction in planning, developing and enhancing
          the future strategic direction of the Company;

     (l)  share responsibility with the other directors for the effective
          control of the Company and with the other non-executive directors for
          the supervision of the executive directors; and

     (m)  comply with the Financial Services Authority's Model Code for
          securities transactions by directors of listed companies and with any
          code of conduct relating to securities transactions by directors and
          specified employees issued by the Company from time to time.

5.   Overall, the Company anticipates that you will need to spend an average of
     one day per month fulfilling your duties after the induction phase. This
     will include the board meetings, annual general meetings, annual strategy
     meeting and site visits. In addition you will be expected to spend an
     appropriate period of time preparing for each meeting. By accepting this
     appointment you confirm that you are able to commit sufficient time to the
     role to meet the Company's expectations.

6.   The Company seeks to adhere to the principles in the Cadbury Report on
     Corporate Governance, the Greenbury Report on Directors' Remuneration, the
     Hampel Report on Corporate Governance and the Turnbull Report on Internal
     Control. You will be expected to carry out your duties in accordance with
     the principles set out in these reports, copies of which are available from
     the Company Secretary.

7.   The performance of the Board and its committees, and of individual
     directors, is evaluated annually.

<PAGE>

                                       4

8.   You shall, in pursuance of your duties hereunder, be entitled to request
     such information from the Company, its subsidiary undertakings (as defined
     in section 258 of the Companies Act 1985 as amended from time to time) or
     its or their employees, consultants or professional advisers as may be
     reasonably necessary to enable you to perform your role effectively. The
     Company shall use its reasonable endeavours to provide such information
     promptly.

CONFIDENTIALITY

During the course of your duties you will have access to confidential
information belonging to the Company and its subsidiary undertakings
(including, but not limited to, details of suppliers, customers, margins,
know-how, marketing and other relevant business information). Unauthorised
disclosure of this information could seriously damage the Company. You therefore
undertake not to use or disclose such information save in pursuance of your
duties or in accordance with any statutory obligation or court or similar order.

Your attention is drawn to the rules relating to the disclosure of price
sensitive information. You must not make any statement or do anything which may
be a breach of these rules without prior clearance from the Chairman or Company
Secretary.

OUTSIDE INTERESTS

The agreement of the chairman should be sought before you accept any new outside
interests which might affect the time you are able to devote to this
appointment.

In accordance with the principles set out in the Combined Code you must inform
the Board of any interests which you have, or acquire, which might reasonably be
thought to jeopardise your independence from the Company.

During your appointment you must not take up any office or employment with, or
have any interest in, any firm or company which is or may be in direct or
indirect competition with the Company.

The Board have determined you to be independent, according to the provisions of
the Combined Code.

INSURANCE

During your appointment you will be covered by the Company's directors' and
officers' liability insurance on the terms currently in place for the rest of
the Board. The current indemnity limit is L10 million. A copy of the policy
document is available from the Company Secretary. The Company does not guarantee
to maintain this insurance cover after the termination of your appointment, but
you will continue to be covered by the policy or any replacement on the same
basis as the rest of the Board.

<PAGE>

                                        5

APPOINTMENT

Your appointment will commence on 1 August 2005 and is terminable by three
months' notice from either the Company or yourself. It is envisaged that your
appointment will initially be for a term of three years. The continuation of
your appointment depends upon satisfactory performance and re-election at
forthcoming Annual General Meetings.

Not withstanding the aforementioned notice provisions, the Company may terminate
your appointment with immediate effect if you have:

(a)  committed any serious breach or (after warning in writing) any repeated or
     continued material breach of your obligations to the Company (which include
     an obligation not to breach your fiduciary duties);

(b)  been guilty of any act of dishonesty or serious misconduct or any conduct
     which (in the reasonable opinion of the Board) tends to bring you or the
     Company into disrepute; or

(c)  been declared bankrupt or have made an arrangement or composition with of
     for the benefit of your creditors,

or for any other reason set out in the Company's articles of association.

All appointments and reappointments to the Board are, of course, subject to the
Company's articles of association. If you are not re-elected to your position as
a director of the Company by the shareholders at any time and for any reason
then this appointment shall terminate automatically and with immediate effect.

On termination of the appointment you shall only be entitled to such fees as may
have accrued to the date of termination together with reimbursement in the
normal way of any expenses properly incurred prior to that date.

REMUNERATION

The fee is L25,000 per annum (subject to income tax and statutory
deductions) and is payable monthly in arrears. It may be subject to upward
review at the discretion of the Company after one year. If you undertake any
special duties beyond those specified in this letter you will not receive any
additional payment unless agreed with the Board in advance.

EXPENSES

The Company will reimburse you for any expenses that you may incur properly and
reasonably in performing your duties and which are properly documented. Such
expenses would include reasonable legal fees if circumstances should arise in
which it was necessary for you to seek separate legal advice about the
performance of your

<PAGE>

                                        6

duties. In such a situation, you are required to discuss the issue either with
me or with one of your non-executive colleagues in advance.

INDEPENDENT PROFESSIONAL ADVICE

In some circumstances you may think that you need professional advice in the
furtherance of your duties as a director. It may also be appropriate for you to
seek advice from independent advisers at the Company's expense. A copy of the
Board's agreed procedure under which directors may obtain such independent
advice is available from the Company Secretary. The Company will reimburse the
full cost of any expenditure incurred in accordance with the policy.

DATA PROTECTION

By signing this agreement you consent to the Company holding and processing
information about you which you may provide or which it may acquire during the
course of this agreement, providing such use is in accordance with the Data
Protection Act 1998. In particular you consent to the Company holding and
processing:

(a)  personal data relating to you, for administrative and management purposes;
     and

(b)  "sensitive personal data" relating to you (as defined in the Data
     Protection Act 1998) including, for example:

          (i)  your health records and any medical reports given to or obtained
               by the Company, for monitoring sick leave and taking decisions as
               to your fitness to work;

          (ii) your racial or ethnic origin (in order to monitor compliance with
               the Race Relations Act 1976);

          (iii) any information relating to criminal proceedings in which you
               have been involved for compliance with the Company's legal or
               regulatory requirements, for insurance purposes, and in relation
               to its obligations to third parties.

You also consent to the Company making such information available to:

(a)  its group companies, offices and (if necessary) customers outside the
     European Economic Area in order to further its business interests; and

(b)  its group companies, its offices, those who provide products or services to
     the Company, regulatory authorities, governmental or quasi governmental
     organisations and potential purchasers of the Company or its business.

<PAGE>

                                        7

THIRD PARTY RIGHTS

The Contracts (Rights of Third Parties) Act 1999 shall not apply to this
agreement. No person other than the parties to this agreement and any group
company shall have any rights under it and it will not be enforceable by any
person other than those parties.

Please sign and return the enclosed copy of this letter to confirm your
agreement to the above terms. We will separately also ask you to sign a form 288
for filing at Companies House.

The Company looks forward to working with you in the future.

Yours sincerely

/s/ Stuart Wallis
-------------------------------------
Stuart Wallis
for and on behalf of Protherics Plc

I, Bryan Morton, agree to the above terms of appointment as a non-executive
director of Protherics Plc.

Name /s/ Bryan Morton
Date 21 July 2005

In the presence of:

Witness signature:  /s/ A. Kutkus
                    -------------------------
Witness name:       ANNA KUTKUS
Witness address:    10 WALDRON MEWS
                    LONDON SW3 5BT
Witness occupation: DESIGNEREX-10.J FORM OF STOCK APPRECIATION RIGHT AGREEMENT

 

Exhibit 10j.

SERVIDYNE, INC.

2000 STOCK AWARD PLAN

STOCK APPRECIATION RIGHTS AGREEMENT

          THIS
STOCK APPRECIATION RIGHTS AGREEMENT (the “Agreement”) is entered into as of the ___ day
of                     , 200_, by and between SERVIDYNE, INC., a Georgia corporation (the “Company”), and the
employee designated below (the “Participant”).

W I T N E S S E T H:

          WHEREAS, the Servidyne Inc. 2000 Stock Award Plan (the “Plan”) was adopted by the Company,
effective February 3, 2000; and

          WHEREAS, the Committee responsible for administration of the Plan has granted the Participant,
SARs as of the Grant Date specified below;

          NOW, THEREFORE, the parties agree as follows:

	 	 	 	 	 
	Employee/Participant:
	 	 	 	 
	 

	 	 

	 	 
	 
	 	 	 	 
	Number of SARs:

	 	 	 	SARs
	 

	 	 

	 	 
	 
	 	 	 	 
	SAR Exercise Price:
	 	 	 	 
	 
	 	 	 	 
	Grant Date:
	 	 	 	 
	 

	 	 

	 	 

	 	 	 	 	 	 	 
	Vesting Schedule:

	 	% of SARs
	 	 Date
	 

	 	30%	 	 	 	3rd anniversary of Grant Date
	 

	 	30%	 	 	 	4th anniversary of Grant Date
	 

	 	40%	 	 	 	5th anniversary of Grant Date
	 
	 	 	 	 	 	 
	 	 	Provided that
all SARs shall vest and be exercisable on the
10th consecutive
day that the Company’s common stock trades on NASDAQ at or above $20.00 per share.

1. Grant of SARs.

     1.1 Subject to the provisions of the Plan, the Company hereby grants to the Participant the
number of Stock Appreciation Rights (“SARs”) shown above with the exercise price shown above (the
“SAR Exercise Price”). Each SAR represents the right to receive an amount, payable in Shares as
provided in Section 4 below, equal in value to the excess, if any, on the date of exercise of the
Fair Market Value of a Share over the SAR Exercise Price of the SAR. The SARs granted hereby are
free-standing SARs and are not granted in conjunction with an Option. This grant of SARs is
hereinafter called the “Award.”

1

 

     1.2 Construction. This Agreement shall be construed in accordance and consistent
with, and subject to, the provisions of the Plan (the provisions of which are incorporated herein
by reference) and, except as otherwise expressly set forth herein, the capitalized terms used in
this Agreement shall have the same definitions as set forth in the Plan.

     1.3 Condition. The Award is conditioned on the Participant’s execution of this
Agreement. If this Agreement is not executed by the Participant, it may be canceled by the
Committee.

2. Duration.

     The Award shall be exercisable to the extent and in the manner provided herein for a period of
ten (10) years from the Grant Date (the “Exercise Term”); provided, however, that the Award may be
earlier terminated as provided in Section 1.3 and Section 5.

3. Vesting.

     The Award shall vest, and may be exercised, with respect to the SARs, on or after the dates
set forth in the Vesting Schedule above, subject to earlier vesting of the Award as provided herein
and subject to earlier termination of the Award as provided in this Agreement and in the Plan. The
right to exercise the SARs as they become vested shall be cumulative and shall continue during the
Exercise Term unless sooner terminated as provided herein or in the Plan.

4. Manner of Exercise.

     4.1 Exercise. To exercise the Award, the Participant must deliver a completed copy of
the SAR Exercise Form, attached hereto as Exhibit A, to the address indicated on such Form or such
other address designated by the Company from time to time. The Award may be exercised in whole or
in part with respect to the vested SARs; provided, however, the Committee may establish a minimum
number of SARs (e.g., 100) for which an Award may be exercised at a particular time. Upon the
exercise of a SAR, the Participant shall be entitled to receive an amount, equal to the product of
(i) the excess of the Fair Market Value of one Share on the date of exercise over the SAR Exercise
Price of the applicable SAR, multiplied by (ii) the number of Shares in respect to which the SAR
has been exercised. Except as otherwise determined by the Committee, the payment shall be made in
Shares based upon the Fair Market Value of a Share on the date of exercise. Fractional Shares
shall be settled by payment in cash based upon the Fair Market Value on such date.

     4.2 No Rights as Shareholder. The Participant shall not be deemed to be the holder
of, or to have any of the rights of a holder with respect to any Shares subject to the Award until
the SAR shall have been exercised pursuant to the terms of this Agreement and the Company shall
have issued the Shares to the Participant (either by delivery to the Participant or his designee of
certificates evidencing the Shares or by having the Participant’s name entered as a shareholder of
record of the Company), whereupon the Participant shall have full voting and other ownership rights
with respect to such Shares.

2

 

5. Termination of Employment.

     5.1 Termination for Cause. If the Participant’s employment is terminated by the
Company for Cause, all outstanding unvested SARs shall immediately expire and be forfeited, and the
Participant’s right to exercise the SARs (whether or not vested) shall terminate immediately upon
the date that the Committee determines is the Participant’s date of termination of employment.

     5.2 Termination by Death. In the event the Participant dies while actively employed
by the Company, all outstanding unvested SARs granted to the Participant shall immediately vest,
and thereafter all vested SARs shall remain exercisable at any time prior to the end of the
Exercise Term, or for one (1) year after the date of death, whichever period is shorter, by such
person(s) as shall have been named as the Participant’s beneficiary, or in the absence of a
designated beneficiary, by the executor or representative of the Participant’s estate.

     5.3 Termination by Disability. If Participant’s employment with the Company is
terminated by reason of Disability, all outstanding unvested SARs granted to the Participant shall
immediately vest as of the date the Committee determines the definition of Disability to have been
satisfied by the Participant, and thereafter all vested SARs shall remain exercisable at any time
prior to the end of the Exercise Term, or for one (1) year after the date that the Committee
determines the definition of Disability to have been satisfied, whichever period is shorter.

     5.4 Termination for Other Reasons. If the Participant’s employment with the Company
is terminated by the Company without Cause or the Participant voluntarily terminates his employment
for any reason, all outstanding unvested SARs shall immediately expire on the date of termination
of employment. Any SARs vested as of the date of termination shall remain exercisable at any time
prior to the end of the Exercise Term or for ninety (90) days after the date of termination of
employment, whichever period is shorter.

     5.5 Employment with a Subsidiary; Service other than Employment. For purposes of this
Section and Section 9, employment with the Company includes employment with any Subsidiary of the
Company. If the Participant is a Director, all references to employment shall mean the Director’s
service as a Director, and termination of employment shall mean termination of the Participant’s
service as a Director. If the Participant is not an employee or a prospective employee on the
Grant Date, but rather provides consulting services or other services as a non-employee of the
Company, all references to employment shall mean the Participant’s engagement as a service provider
to the Company and the Participant shall be deemed to terminate employment when the Participant
ceases to provide or be engaged to provide services to the Company. The Committee shall determine
when the Participant ceases to provide or be engaged to provide services to the Company.

6. Nontransferability.

     The Award shall not be transferable other than by will or by the laws of descent and
distribution, and during the lifetime of the Participant, the Award shall be exercisable only by
the Participant.

3

 

7. Securities Laws Restrictions.

     The Award may not be exercised at any time unless, in the opinion of counsel for the Company,
the issuance and sale of the Shares issued upon such exercise is exempt from registration under the
Securities Act of 1933, as amended, or any other applicable federal or state securities law, rule
or regulation, or the Shares have been duly registered under such laws. The Company intends to
register the Shares issuable upon the exercise of the Award; however, until the Shares have been
registered under all applicable laws, the Participant shall represent, warrant and agree, as a
condition to the exercise of the Award, if such exercise is permitted by the Committee, that the
Shares are being acquired for investment only and without a view to any sale or distribution of
such Shares and that such Shares shall not be transferred or disposed of in any manner without
registration under such laws, unless it is the opinion of counsel for the Company that such a
disposition is exempt from such registration. The Participant acknowledges that an appropriate
legend giving notice of the foregoing restrictions shall appear conspicuously on all certificates
evidencing the Shares issued upon the exercise of the Award.

8. Effect of Change in Control or Significant Corporate Event.

     In the event of a proposed sale of all or substantially all of the assets or stock of the
Company, the merger of the Company with or into another corporation such that shareholders of the
Company immediately prior to the merger exchange their Shares of stock in the Company for cash
and/or shares of another entity or any other Change in Control or corporate transaction to which
the Committee deems this provision applicable (any such event is referred to as a
“Transaction”), the Committee may, in its discretion, without consent of the Participant:

          (a) cause the SARs to be assumed, or arrange for the substitution, in exchange for the SARs,
of SARs to purchase equity securities other than Shares (including, if appropriate, equity
securities of an entity other than the Company), on such terms and conditions as the Committee
determines are appropriate;

          (b) accelerate the vesting of or right to exercise the SARs immediately prior to or in
connection with the closing or completion of any such Transaction, and cause the expiration of the
SARs to the extent not timely exercised by the date of the closing or completion of any such
Transaction or other date designated by the Committee; and/or

          (c) cancel or arrange for the cancellation of all or any portion of the SARs in exchange for a
cash payment equal to the difference between the Fair Market Value of the SARs being canceled
(including SARs that would not otherwise be vested) and the SAR Exercise Price for such SARs,
computed as of the date of the Change in Control and to be paid no later than 3 business days after
the Change in Control.

9. No Right to Continued Employment.

     Nothing in this Agreement or the Plan shall be interpreted or construed to confer upon the
Participant any right with respect to continuance of employment by the Company or any Subsidiary,
nor shall this Agreement or the Plan interfere in any way with the right of the Company or a
Subsidiary to terminate the Participant’s employment at any time.

4

 

10. Adjustments.

     In the event of a Change in Capitalization, the Committee may make appropriate adjustments to
the number and class of Shares or other stock or securities subject to the Award and the SAR
Exercise Price for such Shares or other stock or securities. The Committee’s adjustment shall be
made in accordance with the provisions of Section 4.3 of the Plan and shall be effective and final,
binding and conclusive for all purposes of the Plan and this Agreement.

11. Withholding of Taxes.

     The Company shall have the right to deduct from any distribution of cash to the Participant an
amount equal to the federal, state and local income taxes and other amounts as may be required by
law to be withheld (the “Withholding Taxes”) with respect to the Award. If the Participant is
entitled to receive Shares upon exercise of the SAR, the Participant may pay the Withholding Taxes
to the Company in cash prior to the issuance of such Shares or the Participant may make a written
election to have withheld a portion of the Shares issuable to him or her upon exercise of the SARs,
having an aggregate Fair Market Value equal to the Withholding Taxes, provided that, if the
Participant may be subject to liability under Section 16(b) of the Exchange Act, the election must
comply with the requirements applicable to Share transactions by such Participant. In addition,
the Company shall be authorized to withhold the Withholding Taxes from other compensation payable
by the Company to the Participant.

12. Modification of Agreement.

     Except as provided in Section 8 and Section 10, this Agreement may be modified, amended,
suspended or terminated, and any terms or conditions may be waived, only by a written instrument
executed by the parties hereto.

13. Severability.

     Should any provision of this Agreement be held by a court of competent jurisdiction to be
unenforceable or invalid for any reason, the remaining provisions of this Agreement shall not be
affected by such holding and shall continue in full force in accordance with their terms.

14. Section 409A.

     This Agreement shall be interpreted and applied so that the SARs are exempt from, and will not
be subject to, Code Section 409A. In addition, this Agreement shall be interpreted and applied as
if it contained any additional provisions that it is required to contain in order for the SARs to
be exempt from Code Section 409A.

15. Governing Law.

     The validity, interpretation, construction and performance of this Agreement shall be governed
by the laws of the State of Georgia without giving effect to the conflicts of laws principles
thereof.

5

 

16. Successors in Interest.

     This Agreement shall inure to the benefit of and be binding upon each successor corporation to
the Company. This Agreement shall inure to the benefit of the Participant’s legal representatives.
All obligations imposed upon the Participant and all rights granted to the Company under this
Agreement shall be final, binding and conclusive upon the Participant’s heirs, executors,
administrators and successors.

17. Resolution of Disputes.

     Any dispute or disagreement which may arise under, or as a result of, or in any way relate to,
the interpretation, construction or application of this Agreement shall be determined by the
Committee. Any determination made hereunder shall be final, binding and conclusive on the
Participant and the Company for all purposes.

     IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the date first
above written.

	 	 	 	 	 
	 	 	SERVIDYNE, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 
	 

     By signing below, Participant hereby accepts the Award subject to all its terms and provisions
and agrees to be bound by the terms and provisions of the Plan. Participant hereby agrees to
accept as binding, conclusive and final all decisions or interpretations of the Committee
responsible for administration of the Plan, upon any questions arising under the Plan. Participant
authorizes the Company to withhold, in accordance with applicable law, from any compensation
payable to him or her, any taxes required to be withheld by federal, state or local law as a result
of the grant, existence or exercise of the Award.

	 	 	 	 	 
	 

	 	 	 	PARTICIPANT
	 
	 	 	 	 
	 

	 	Signature:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 

[EXHIBIT FOLLOWS]

6

 

EXHIBIT A

SAR EXERCISE FORM

     I,
«Name» , do hereby exercise the Award with a Grant Date of
_________ ___, 200___ granted to me
pursuant to the Stock Appreciation Rights Agreement. The number of SARs being exercised and the SAR
Exercise Price are set forth below:

	 	 	 	 	 
	Number of SARs:

	 	SARs
	 	 
	 
	 	 	 	 
	SAR Exercise Price

	 	$ ______ per SAR	 	 

	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	Signature

	 	Date:	 	 	 	 
	 

	 	 	 	 

	 	 

Send or deliver this Form with an original signature to:

Servidyne, Inc.

1945 The Exchange, Suite 300

Atlanta, Georgia 30339

Attn: [Chief Financial Officer]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]